Merck Millipore Launches Single-Use Process Container Film for High-Volume Biopharmaceutical Applications
Merck Millipore has expanded its single-use film offerings with the introduction of PureFlex Plus film, a robust, durable film used in the construction of Mobius single-use process containers for biopharmaceutical manufacturing. The film's rugged outer layer offers strong resistance to leak formation, making it ideal for the demanding applications often encountered in large volume operations.
PureFlex Plus film adds a new, more robust linear low density polyethlene (LLDPE) outer layer, which reduces susceptibility to leaks through abrasion, puncture, stretching and tearing. The inner layers of PureFlex Plus film are identical to the original PureFlex film product and offer the same well-characterised extractables profile and gas barrier properties. Because the fluid contact layer is the same in both films, current users of PureFlex film can incorporate PureFlex Plus technology with reduced validation requirements. Original PureFlex film will remain available, however, for customers uninterested in a film change.
"Biopharmaceutical manufacturers are increasingly incorporating single-use components into their processes to maximise efficiency and reduce costs," said Andrew Bulpin, Executive Vice President of Merck Millipore, Process Solutions. "The versatility of the single-use PureFlex film has allowed it to be used throughout the entire production process, limiting validation and implementation effort. The enhanced PureFlex Plus film adds further robustness to our proven film technology, helping to ensure process container integrity even in physically stressful applications."
Similar to its predecessor, PureFlex Plus film is a high purity, medical grade, coextruded film designed to provide strength, flexibility, low gas permeability, and an inert product contact layer. The fluid contact material is made of ultra low density polyethylene (ULDPE), the gas barrier layer is made of polyethylene vinyl alcohol copolymers (EVOH), and the first outer layer is made of ethylene vinyl acetate (EVA). All contact layers are free of animal-derived components and comply with the FDA regulation 21 CFR 177.1520. Using Merck Millipore's EZ fold technology, these flexible films allow for high-volume bag assemblies (> 500 L) to be filled in a bin without operator manipulation or the use of a hoist.
PureFlex films are used in the construction of Merck Millipore's Mobius assemblies and NovaSeptum sterile sampling products, which can be customised for any application. Business continuity plans have been established to ensure uninterrupted global supply of these films and products.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance